Raymond James Financial’s Dianthus Therapeutics DNTH Stock Holding History
Bought
Maintained
Sold
Other funds holding DNTH
Raymond James Financial's DNTH Position: Q3 2026 in Review
Raymond James Financial increased its Dianthus Therapeutics (DNTH) stake by 20% in Q3 2026, buying an estimated $90.5K and bringing the position to 5,210 shares worth $459K. The position accounts for ﹤0.01% of the portfolio, ranked #4614.
Raymond James Financial first reported a position in DNTH in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.27M in Q1 2026. 275 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.
- Raymond James Financial held 5,210 shares of Dianthus Therapeutics worth $459K as of Q3 2026.
- Raymond James Financial bought 872 Dianthus Therapeutics shares in Q3 2026, an estimated $90.5K.
- Dianthus Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #4614 holding.
- Raymond James Financial first reported a position in Dianthus Therapeutics in Q2 2025 and has held it in 5 quarters since.
- Raymond James Financial's Dianthus Therapeutics position peaked at $1.27M in Q1 2026.
- 275 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.
Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.